Compare QSR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QSR | GMAB |
|---|---|---|
| Founded | 1954 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 20.6B |
| IPO Year | 2006 | N/A |
| Metric | QSR | GMAB |
|---|---|---|
| Price | $66.94 | $31.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $73.94 | $40.40 |
| AVG Volume (30 Days) | ★ 2.8M | 1.5M |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 132.41 |
| EPS | 2.81 | ★ 25.10 |
| Revenue | ★ $9,264,000,000.00 | $3,845,670,022.00 |
| Revenue This Year | $12.57 | $24.85 |
| Revenue Next Year | $3.92 | $16.51 |
| P/E Ratio | $24.17 | ★ $1.27 |
| Revenue Growth | 16.82 | ★ 29.57 |
| 52 Week Low | $58.71 | $17.24 |
| 52 Week High | $73.70 | $33.96 |
| Indicator | QSR | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 50.12 |
| Support Level | $68.80 | $30.35 |
| Resistance Level | $70.05 | $33.96 |
| Average True Range (ATR) | 0.96 | 0.61 |
| MACD | -0.42 | -0.17 |
| Stochastic Oscillator | 8.30 | 39.61 |
Restaurant Brands generates about $44 billion in system sales across more than 32,000 restaurants in over 120 markets, making it one of the largest restaurant companies globally. Its banners include Burger King (7,082 stores), Tim Hortons (4,539), Popeyes (3,520), and Firehouse Subs (1,345), concentrated in the US and Canada, with these brands also comprising 15,639 franchised international locations as of year-end 2024. The firm primarily earns revenue from franchise and property fees, supply chain sales within the Tim Hortons segment, company-operated restaurants, and advertising royalties.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.